{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:02:45Z","timestamp":1792515765338,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["journal-of-hepatology.eu","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.jhep.2016.02.043","type":"journal-article","created":{"date-parts":[[2016,3,5]],"date-time":"2016-03-05T22:43:40Z","timestamp":1457217820000},"page":"280-288","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":138,"title":["Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma \u2013 The SHELTER study"],"prefix":"10.1016","volume":"65","author":[{"given":"Michael","family":"Bitzer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius","family":"Horger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo G.","family":"Giannini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom M.","family":"Ganten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus A.","family":"W\u00f6rns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens T.","family":"Siveke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias M.","family":"Dollinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Gerken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max E.","family":"Scheulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"Wege","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorina","family":"Zagonel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Cillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Trevisani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Montesarchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisar P.","family":"Malek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Holzapfel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Herz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid S.","family":"Ammendola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Pegoraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Hauns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Mais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich M.","family":"Lauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan W.","family":"Henning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Hentsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2016.02.043_b0005","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21161","article-title":"Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma","volume":"62","author":"Maluccio","year":"2012","journal-title":"Cancer J Clin"},{"key":"10.1016\/j.jhep.2016.02.043_b0010","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2016.02.043_b0015","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.1200\/JCO.2012.45.8372","article-title":"Sunitinib vs. sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial","volume":"31","author":"Cheng","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2016.02.043_b0020","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1200\/JCO.2013.54.3298","article-title":"Linifanib vs. sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial","volume":"33","author":"Cainap","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2016.02.043_b0025","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1200\/JCO.2012.48.4410","article-title":"Brivanib vs. sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the phase III BRISK-FL study","volume":"31","author":"Johnson","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2016.02.043_b0030","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1200\/JCO.2012.47.3009","article-title":"Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study","volume":"31","author":"Llovet","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2016.02.043_b0035","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1111\/j.1745-7254.2005.00195.x","article-title":"Histone deacetylase inhibitors for treatment of hepatocellular carcinoma","volume":"26","author":"Coradini","year":"2005","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.jhep.2016.02.043_b0040","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000111106","article-title":"Clinical significance of histone deacetylase 1 expression in patients with hepatocellular carcinoma","volume":"72","author":"Rikimaru","year":"2007","journal-title":"Oncology"},{"key":"10.1016\/j.jhep.2016.02.043_b0045","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1002\/hep.27131","article-title":"Epigenetics in liver disease","volume":"60","author":"Mann","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.02.043_b0050","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","article-title":"A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations","volume":"141","author":"Sharma","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.jhep.2016.02.043_b0055","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jhep.2004.10.020","article-title":"Apoptosis on hepatoma cells but not on primary hepatocytes by histone deacetylase inhibitors valproate and ITF2357","volume":"42","author":"Armeanu","year":"2005","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.02.043_b0060","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1002\/cncr.22652","article-title":"Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma","volume":"109","author":"Venturelli","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.jhep.2016.02.043_b0065","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.jhep.2012.01.009","article-title":"Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib","volume":"56","author":"Lachenmayer","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.02.043_b0070","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1200\/JCO.2011.41.2395","volume":"30","author":"Yeo","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2016.02.043_b0075","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-13-0735","article-title":"First-in-human, pharmacokinetic and pharmacodynamic phase I study of Resminostat, an oral histone deacetylase inhibitor, in patients with advanced solid tumors","volume":"19","author":"Brunetto","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhep.2016.02.043_b0080","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","article-title":"American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update","volume":"53","author":"Bruix","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.02.043_b0085","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumors: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jhep.2016.02.043_b0090","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.jhep.2016.02.043_b0095","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1002\/hep.24644","article-title":"Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy","volume":"54","author":"Iavarone","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.02.043_b0100","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1634\/theoncologist.2012-0221","article-title":"A phase II randomized dose escalation trial of sorafenib in patients with advanced hepatocellular carcinoma","volume":"18","author":"Rimassa","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.jhep.2016.02.043_b0105","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/hep.510270106","article-title":"Q-T Prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors","volume":"27","author":"Bernardi","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.02.043_b0110","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1155\/2013\/170546","article-title":"In a \u2018real-world\u2019, clinic-based community setting, sorafenib dose of 400 mg\/day is as effective as standard dose of 800 mg\/day in patients with advanced hepatocellular carcinoma, with better tolerance and similar survival","volume":"27","author":"Shingina","year":"2013","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.jhep.2016.02.043_b0115","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/ijcp.12352","article-title":"GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment withsorafeNib): second interim analysis","volume":"68","author":"Lencioni","year":"2014","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jhep.2016.02.043_b0120","first-page":"129","article-title":"The development and potential clinical utility of biomarkers for HDAC inhibitors","volume":"7","author":"Shi","year":"2013","journal-title":"Drug Discov Ther"},{"key":"10.1016\/j.jhep.2016.02.043_b0125","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1242\/jcs.023119","article-title":"Zfp64 participates in Notch signaling and regulates differentiation in mesenchymal cells","volume":"121","author":"Sakamoto","year":"2008","journal-title":"J Cell Sci"},{"key":"10.1016\/j.jhep.2016.02.043_b0130","doi-asserted-by":"crossref","first-page":"24600","DOI":"10.1074\/jbc.M113.473397","article-title":"Zinc finger protein 64 promotes Toll-like receptor-triggered proinflammatory and type I interferon production in macrophages by enhancing p65 subunit activation","volume":"288","author":"Wang","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jhep.2016.02.043_b0135","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.ccr.2012.02.007","article-title":"Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4","volume":"21","author":"Dapito","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jhep.2016.02.043_b0140","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1053\/j.gastro.2012.09.002","article-title":"Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice","volume":"143","author":"Villanueva","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2016.02.043_b0145","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1182\/blood.V118.21.2675.2675","article-title":"Final results of the phase II SAPHIRE trial of resminostat (4SC-201) in patients with relapsed\/refractory hodgkin lymphoma [Abstract]","volume":"118","author":"Walewski","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jhep.2016.02.043_b0150","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1470-2045(12)70490-4","article-title":"Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study","volume":"14","author":"Santoro","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2016.02.043_b0155","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1002\/hep.26586","article-title":"Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design","volume":"58","author":"Reig","year":"2013","journal-title":"Hepatology"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827816300095?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827816300095?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T18:22:20Z","timestamp":1600280540000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827816300095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["S0168827816300095"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2016.02.043","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma \u2013 The SHELTER study","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2016.02.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}